
Retatrutide
LY3437943
Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.
Complete Dosing Guide
Quick Reference
Administration Method
Subcutaneous injection once weekly
Step-by-Step Dosing Protocol
Dosing Guidelines
Standard escalation begins with 2.4 mg weekly for 4 weeks, followed by 4.8 mg weekly for 4 weeks. Further increases to 7.2 mg and maximum 12 mg weekly should occur at 4-week intervals based on clinical response and tolerability. Most patients achieve optimal results at 7.2-12 mg weekly for weight management.
You always start low and go slow with Retatrutide. Everyone starts with 2.4mg once a week for a month. Then you increase by 2.4mg every month until you find the dose that works best for you, up to 12mg per week maximum. Most people end up taking 7.2-12mg per week for the best weight loss results.
Mixing & Injection
Subcutaneous injection using pre-filled pens or vials with separate syringes. Injection sites include abdomen, thigh, or upper arm. Rotate injection sites weekly to prevent lipodystrophy. Administer on the same day each week, any time of day, with or without meals. If dose is missed, administer as soon as possible if within 4 days, otherwise skip and resume regular schedule.
Subcutaneous injection using pre-filled pens or vials with separate syringes. Injection sites include abdomen, thigh, or upper arm. Rotate injection sites weekly to prevent lipodystrophy. Administer on the same day each week, any time of day, with or without meals. If dose is missed, administer as soon as possible if within 4 days, otherwise skip and resume regular schedule.
Clinical Administration Guidelines
Injection Protocol
- •Subcutaneous injection per protocol
- •Rotate injection sites
- •Consistent daily timing
- •Follow protocol guidelines
Monitoring Schedule
- •Regular progress monitoring
- •Health parameter monitoring
- •Laboratory monitoring
- •Safety monitoring
Dosage Calculator
Medical Disclaimer
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.